Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss Drug's effect on other medications tested in healthy volunteers

NCT ID NCT06186622

Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study looked at how orforglipron, an experimental drug, changes the way the body processes several common medications (digoxin, simvastatin, rosuvastatin, acetaminophen, and midazolam) in 50 healthy overweight or obese adults. The goal was to measure drug levels in the blood, not to treat any disease. Participants took each medication alone and then with orforglipron to see if there were differences. The study provides important safety information for future use of orforglipron.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

50 people

The number who actually took part.

Started

Jan 2024

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who are overtly healthy as determined by medical history and physical examination. * Have body mass index (BMI) equal to or greater than 27 kilograms per meter squared (kg/m²), inclusive, at screening. * Have an estimated glomerular filtration rate equal to or greater than 60 milliliters per minute (mL/min). * Males and females who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP). * Have venous access sufficient to allow for blood sampling. Exclusion Criteria: * Have any type of diabetes with hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater. * Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years. * Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome. * Have known clinically significant gastric emptying abnormality. * Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass) * Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer. * Have an abnormal 12-lead electrocardiogram (ECG) at screening. * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug. * Participants must not be currently participating in or completed a clinical trial within the last 90 days. * Have a known allergy or hypersensitivity to midazolam, simvastatin, rosuvastatin, or digoxin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy OBESE Overweight

Contacts and locations

Locations

  • Fortrea Clinical Research Unit Inc.

    Daytona Beach, Florida, 32117, United States

  • Fortrea Clinical Research Unit Inc.

    Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.